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Astrocytes are responsible for regulating extracellular levels of glutamate and potassium during 
neuronal activity. Glutamate clearance is handled by glutamate transporter subtypes glutamate 
transporter 1 and glutamate-aspartate transporter in astrocytes. DL-threo-β-benzyloxyaspartate 
(TBOA) and dihydrokainate (DHK) are extensively used as inhibitors of glial glutamate transport 
activity. Using whole-cell recordings, we characterized the effects of both transporter inhibitors 
on afferent-evoked astrocyte currents in acute cortical slices of 3-week-old rats. When neuronal 
afferents were stimulated, passive astrocytes responded by a rapid inward current followed by a 
persistent tail current. The first current corresponded to a glutamate transporter current. This 
current was inhibited by both inhibitors and by tetrodotoxin. The tail current is an inward 
potassium current as it was blocked by barium. Besides inhibiting transporter currents, TBOA 
strongly enhanced the tail current. This effect was barium-sensitive and might be due to a rise in 
extracellular potassium level and increased glial potassium uptake. Unlike TBOA, DHK did not 
enhance the tail current but rather inhibited it. This result suggests that, in addition to inhibiting 
glutamate transport, DHK prevents astrocyte potassium uptake, possibly by blockade of inward-
rectifier channels. This study revealed that, in brain slices, glutamate transporter inhibitors exert 
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Neuronal activity at glutamatergic synapses leads to substantial glutamate release and K+ efflux 
in the extracellular space. The clearance of both glutamate and K+ are crucial functions of 
astrocytes in the nervous system. By rapidly taking up extracellular glutamate, astroglial cells 
protect neurons from the excitotoxic buildup of glutamate and ensure the fidelity of 
glutamatergic transmission at high frequency (Danbolt, 2001). For that purpose, astrocytes are 
equipped with efficient glutamate transporters that surround the synaptic cleft and use the 
electrochemical gradient of Na+ to take up glutamate. Among the five subtypes that have been 
identified so far, both glutamate-aspartate transporter (GLAST) and glutamate transporter 1 
(GLT-1) are expressed by glial cells and account for most of the glutamate uptake activity in the 
CNS (Danbolt, 2001). In parallel to the glutamate clearance, glial cells express inwardly 
rectifying K+ (Kir) channels to enable K+ regulation. Within the seven described Kir families, the 
Kir4.1 subtype is almost exclusively expressed by glia in the CNS (Higashi et al., 2001; Butt and 
Kalsi, 2006). 
Inhibitors of glutamate transporters are inevitably crucial tools for elucidating the 
physiological roles of these transporters in detail. Several compound have traditionally been 
used to inhibit glutamate transport, such as threo-β-hydroxyaspartate and trans-pyrrolidine-2,4-
dicarboxylic acid, both of which are transported competitive inhibitors without subtype selectivity 
(Chatton et al., 2001). More recently, the compound DL-threo-β-benzyloxyaspartate (TBOA) has 
been introduced and then widely used as a non-transported competitive inhibitor of glutamate 
transporters (Shimamoto et al., 1998). TBOA, however, has a similar affinity for all subtypes of 
glutamate transporters (Shimamoto et al., 2004). The compound dihydrokainate (DHK) has 
been early on identified as a GLT-1 selective inhibitor. Most studies on the effects of transport 
inhibitors have been performed on primary cultured cells (e.g. Chatton et al., 2001) or have 
focused on the effects of these transporter inhibitors on expression systems such as COS-1 
cells or mRNA-injected Xenopus oocytes (Shimamoto et al., 1998; Shimamoto et al., 2004). 
Despite the lack of data on their effects in experimental preparations where cellular interactions 
are preserved, both TBOA and DHK are now extensively used to block glial glutamate transport 
in studies investigating neuron-glia interactions (see Volterra and Meldolesi, 2005 for an 
extensive review on neuron-glia interactions). Moreover, since glial glutamate transport 
dysfunction has been proposed to have a central role in mood disorder (Sanacora et al., 2003), 
glutamate transporter inhibitors start to be used as novel treatment directions for these 
pathologies (Lee et al., 2007). 





The evoked whole-cell events recorded from astrocytes in acute slices are characterized by 
a first short-lived inward current, previously identified as reflecting glutamate transporter activity 
(Bergles and Jahr, 1997). This initial current is followed by a low amplitude sustained inward 
current described in the literature as being an inward K+ current consecutive to the increased 
extracellular K+ caused by neuronal activity (Bergles and Jahr, 1997; De Saint Jan and 
Westbrook, 2005). This K+ influx, which is mediated by Kir channels (Newman, 1993), 
participates to the astrocytic K+ buffering processes (Walz, 2000; Wallraff et al., 2006). 
In the presents study, we evaluated the effects of the two widely used inhibitors of glutamate 
transporters, TBOA and DHK, on glutamate transporter currents and potassium uptake in 
astrocytes in brain slices. We found that they have different effects on the overall astrocytic 
response. 





 2. Results  
Two main types of astroglial cells coexist in the developing rat brain (Steinhauser et al., 1994). 
The so-called passive astrocytes are characterized by their expression of glutamate 
transporters, as seen by the transporter currents recorded following neuronal afferent 
stimulation (Zhou et al., 2006). Complex or rectifying cells are characterized by the absence of 
significant glutamate transporter activity, with however, expression of ionotropic glutamate 
receptors (Matthias et al., 2003; Wallraff et al., 2004). Here, in slices of the somato-sensory 
cortex acutely isolated from 15- to 21-days old rats, the presence of these two types of 
astrocytes was also observed. Slices were visualized on an upright microscope equipped with 
infrared–differential interference contrast. Astroglial cells were selected in layer I by their small 
soma size (<10µm), and then recorded in whole-cell configuration. Their complex morphology 
was verified by tridimensional reconstruction from confocal fluorescent images of the cell filled 
with Lucifer Yellow (LY, 500µM) through the patch pipette (Fig. 1A). By doing so, 71% of the 
patched cells were found to be passive astrocytes. They were identified by their linear current-
voltage (I-V) relationship (Fig. 1B), the lack of action potentials, their very negative resting 
potential (-81.0 ± 1.1mV), their high membrane capacitance (348 ± 172pF) and the very low 
membrane resistance (15.0 ± 4.5MOhm). Complex astrocytes were recognized by a less 
negative potential (-77.1 ± 1.9mV), a higher membrane resistance (177 ± 37MOhm), a lower 
membrane capacitance (69.8 ± 11.5pF) and a non-linear I-V curve (Fig. 1C). The present study 
focuses on passive astrocytes. 
When neuronal afferents were electrically stimulated, passive astrocytes displayed a rapid 
inward current followed by a persistent inward current (Fig. 2A). The rapid current was inhibited 
by glutamate transport inhibitors TBOA (Figs. 2A and C) and DHK (see below Fig. 3A) and 
displayed a time to peak of 12.7±1.2msec with a maximum amplitude of -111.5±15.9 pA (n=10). 
Moreover, this current was neuronal activity-dependent as its amplitude was proportional with 
the intensity of the applied stimulation and disappeared in the presence of TTX (1µM, not 
shown). These data suggest that this current corresponds to a glutamate transporter current 
(ITrsp) as described previously (Bergles and Jahr, 1997). ITrsp was followed by a persistent “tail 
current” (ITail). This current was an inward current of low amplitude that monotonically reached 
baseline levels after 8.0±1.0 seconds (Time to baseline, n=10 exp, Fig. 2A). Whereas TBOA 
applied alone almost entirely inhibited ITrsp within 4±1 minutes of application, it dramatically 
changed the ITail time course and amplitude (Figs. 2A and B). Under TBOA, Itail displayed a 3-
fold enhancement of its maximum amplitude (Fig. 2C), and a 2.5 fold increased of the time 
needed for return to baseline (Fig. 2C).  





Astrocytes are generally considered to have a very negative (-70-80mV) and stable resting 
membrane potential. We nevertheless tested whether in these situations membrane potential 
was altered during evoked neuronal activity, and analyzed these astrocytic responses in 
current-clamp mode. We observed that cells responded to afferent stimulations by small and 
transient depolarizations of ~3mV that were inhibited by TBOA (Fig. 2D), therefore assigned to 
transporter-activity (VTrsp). Following this transient, a persistent increased potential lasting 
several seconds was observed. Interestingly, and consistent with voltage-clamp measurements, 
in the presence of TBOA, this persistent increased membrane potential (VTail) showed a >2-fold 
increase (Figs. 2D and E). These results are consistent with the notion that TBOA leads to an 
enhancement of the extracellular K+ concentration during the firing of presynaptic afferents. 
In order to verify whether ITail has indeed a K+ origin, as suggested by others (Bergles and 
Jahr, 1997; De Saint Jan and Westbrook, 2005; Meeks and Mennerick, 2007), we applied 
200µM Ba2+ in the bath (Fig. 3A). At this concentration, which effectively blocks Kir channels of 
glial cells (Newman, 1993), Ba2+ inhibited the majority of ITail, and had a slight but non-significant 
inhibitory effect on Itrsp, possibly reflecting a modest effect on neuronal transmitter release. 
Moreover, when Ba2+ and TBOA were applied in combination, both ITrsp and ITail essentially 
disappeared (Fig. 3A). Accordingly, the time to baseline in the presence of Ba2+ was markedly 
reduced (Fig. 3A). Thus, the massive enhancement of ITail caused by TBOA was absent in the 
presence of Ba2+, indicating that this current had effectively a K+ origin. 
If the Itail enhancement by TBOA was due to astrocytic K+ influx through Kir conductances, 
other glutamate transporter inhibitors would be expected to have similar effects on ITail. We 
therefore tested DHK, another non-transported glutamate transporter inhibitor. As expected, Fig. 
3B shows that DHK (100-300µM) inhibited ITrsp by 50-70%. The maximal inhibition was of the 
same magnitude as with TBOA. In contrast to TBOA, not only did DHK fail to enhance ITail, but it 
actually prevented its manifestation. Thus, DHK application led to the same response pattern as 
the addition of TBOA and Ba2+ together. Moreover, in the presence of DHK, the whole-cell 
current voltage-relationship curve of the cell measured from the baseline (e.g. in non-evoked 
astrocytic currents condition), showed a significantly decreased slope indicative of an increased 
input resistance (Fig. 3C), and a shift of the membrane potential to more depolarized values, 
consistent with the notion that DHK leads to a closure of conductances. All together these 
results could indicate that, in addition to inhibiting glutamate transport, DHK also prevents 
astrocyte K+ uptake. 
 






The effects of inhibition of glial glutamate transport in the intact tissue have been most often 
discussed in terms of glutamate spill-over from the synaptic cleft and its action on neuronal 
extrasynaptic receptors (Volterra and Meldolesi, 2005). The present study demonstrates that 
glutamate transporter inhibitors exert different effects on the astrocytic K+ response to neuronal 
stimulation, which are not attributable solely to glutamate transport inhibition. 
In agreement with previous reports, TBOA efficiently inhibited the first, transporter-mediated, 
component. However, a large inward current was then observed that lasted for several seconds. 
The onset of this current corresponded to that of the tail current attributed to K+ uptake; however 
its amplitude and duration were up to 3-fold increased. Because this enhanced current was 
abolished by barium, it could be attributed to an enhancement of astrocytic K+ uptake. It has to 
be borne in mind that inhibiting glutamate transport in the intact tissue causes the accumulation 
of extracellular glutamate which strongly enhances neuronal excitability, even leading to 
epileptiform activity (Campbell and Hablitz, 2004). The enhancement of activity is therefore most 
likely accompanied by substantial K+ accumulation in the extracellular space. 
This observation is possibly similar to what was reported in cerebellar slices, where a slow 
inward current was observed in Bergmann glial (Bellamy and Ogden, 2005). This current was 
enhanced by TBOA and was proposed to be caused by a paracrine messenger released from 
neurons to activate a G-protein coupled receptor in Bergman glia eventually opening some 
conductance. It should be noted that only a couple of studies have documented the TBOA 
potentiation of the K+ current (Bellamy and Ogden, 2005; De Saint Jan and Westbrook, 2005), 
probably because most of other studies have focused on the transporter component.  
During the course of this study, we reasoned that a similar pattern of responses should be 
observed in the presence of the other widely used non-transported glutamate transporter 
inhibitor DHK. Whereas TBOA inhibits all transporter subtypes (Shimamoto et al., 2004), DHK 
acts selectively on the GLT-1 subtype. In the same experimental conditions, both DHK and 
TBOA inhibited the transporter current. Unexpectedly, DHK not only failed to enhance the tail 
current, but it completely prevented its manifestation. Potency of DHK at GLT-1 is relatively low 
with an IC50 of 56µM (Shimamoto et al., 2004) and DHK displays binding at kainate receptors at 
concentrations similar to those required for GLT1 inhibition, as well as weak antagonistic effects 
of NMDA receptors (Selkirk et al., 2005). The present study unveiled a new aspect of DHK 
effects in situ, being that, in addition to inhibiting glutamate transport, DHK prevented astrocyte 
K+ uptake, possibly by blockade of inward-rectifier channels.  





Because of the different selectivity of TBOA and DHK for transporter subtypes, one could 
argue the apparent different effects of these inhibitors arise from the subtypes they target. Here, 
TBOA and DHK showed similar maximal inhibitory level of Itrsp, consistent with the fact that 
between postnatal days 15 and 21, both GLT-1 and GLAST are expressed by rat astrocytes. In 
consequence, the observed difference on the K+ current should not be only attributed to a 
different inhibitory level of the two compounds. 
In conclusion, when using glutamate transporter inhibitors to study glutamate transport in 
situ, complex and indirect effects will impinge on the functions not only of astrocytes but also of 
neurons. This study revealed that glutamate transporter inhibitors TBOA and DHK exert 
strikingly different effects on glial responses to neuronal activity. 





4. Experimental Procedure 
4.1. Acute cortical slice preparation 
Experiments were performed on 350µm thick slices of the  somatosensory cortex, identified as 
described previously (Lalo and Kostyuk, 1998; Pankratov et al., 2002). Briefly, after isoflurane 
anesthesia, Sprague-Dawley rats were decapitated. Coronal slices were cut in slice cutting 
solution (SCS) using a vibrating slicer (VT 1000S, Leica, Germany) and kept in artificial 
cerebrospinal fluid (ACSF) at room temperature. The ACSF solution contained (in mM): NaCl 
126, KCl 2.5, NaHCO3 26, CaCl2 2, MgCl2 2, NaH2PO4 1.25, glucose 10, bubbled with 5% 
CO2/95% oxygen. The SCS solution contained (in mM): KCl 2.5, NaHCO3 25, CaCl2 0.5, MgSO4 
7, NaH2PO4 1.25, glucose 25, choline chloride 110, Na-L-ascorbate 11.6, Na-pyruvate 3.1, and 
was bubbled with 5% CO2/95% oxygen. Threo-β-benzyloxyaspartate (TBOA) and dihydrokainic 
acid (DHK) were from Tocris-Anawa Trading (Zürich). Lucifer Yellow was from Molecular 
Probes. All other compounds were from Sigma. 
4.2. Whole-cell electrophysiological recordings and imaging 
Whole-cell voltage- and current-clamp recordings were made with borosilicate glass pipettes 
with a resistance of 5.5-8 MΩ. In voltage-clamp mode, the clamp potential was set at the 
astrocyte resting potential. Recordings were made with an Axopatch 200 amplifier (Axon 
Instruments). Current were filtered at 2 kHz. Data were acquired with a Digidata 1322A (Axon), 
controlled with Pclamp 9 software and analyzed with Clampfit software (Axon). Experiments 
with unstable holding current and/or access resistance were discarded. A period of 5 min was 
routinely allowed after establishment of the whole-cell configuration. The patch-clamp 
intracellular solution contained (in mM): K-gluconate 124, NaCl 6, KCl 6, MgCl2 3, EGTA 1, 
CaCl2 0.5, HEPES 10, glutathione 2, Mg-ATP 3, Na3-GTP 0.3, pH 7.3 (with KOH). 
Excitatory afferents were stimulated by applying a single depolarization square pulse 
(0.25msec) generated by a Grass S8800 stimulator (Astro Med, West Warwick, RI, USA) 
through a concentric bipolar tungsten electrode (Micro Probe, Gaithersburg, MD, USA). The 
stimulating electrode was positioned at least at 150µm from the patch pipette in higher cortical 
layers. The stimulus strength was adjusted to produce astrocytic responses that were ~80% of 
the maximum. Afferent stimulations were generated and recorded every minute during the entire 
experiments. Drugs were applied after 3 control pulses by bath superfusion. Confocal imaging 
was performed using a confocal microscope (LSM 510 Meta). Three dimensional images were 
reconstructed using the software Imaris (Bitplane, Zurich, Switzerland).  





4.3. Data analysis 
For a given experiment, the mean of the three control responses was calculated and used to 
normalize the response expressed in percentage. Data are means ± SEM and are represented 
as percentage of the control current or voltage amplitude. A paired student t-test was performed 
to assess the statistical significance (*, P<0.05; **, P≤0.01; ***, P<0.001). The number n 
represents independent experiments performed on different brain slices. 
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Fig. 1 - Electrophysiological identification of astrocytes. (A). Tridimensional reconstruction from 
confocal fluorescent images of an astroglial cell filled with LY (major tick = 10µm). (B) 
Representative whole-cell current response of a passive astrocyte to 20mV steps of voltage (-
160mV to 20mV). The cell was clamped at -80mV under resting condition. (C) Representative 
current response of a complex glial cell to voltage steps. I-V curve demonstrates outward 
rectification of the peak currents.  
 
Fig. 2 - Effect of TBOA on the voltage and current astrocytic response. (A) Whole-cell voltage 
clamp response of passive astrocyte to brief neuronal stimulation. Dotted lines indicate the 
baseline current level. Bath application of TBOA (100µM) rapidly inhibited ITrsp and increased 
ITail. (B) Timecourse of TBOA effects on ITail and ITrsp. Number of independent experiments for 
each time point is indicated in the graph. (C) The graph shows the effect of TBOA on ITail, ITrsp 
and the time-to-baseline (n=8). (D) Whole-cell current clamp response. A depolarization 
transient accompanied ITrsp and a slight persistent depolarization was observed during ITail (lower 
trace). The fast depolarization was completely abolished by TBOA, whereas the persistent 
depolarization was enhanced. (E) Bar graph showing means of voltage amplitude following 
afferent stimulation in control condition (white bars) and in the presence of TBOA (black bars) 
for both fast (VTrsp) and persistent (VTail) voltage components (n=5).  
 
Fig. 3.- DHK prevents Barium-sensitive evoked current and closes conductances. (A) In the 
presence of Ba2+, most of ITail disappeared (middle trace), leaving ITrsp that could be blocked by 
the glutamate transporter inhibitor TBOA (bottom trace). Bath application of Ba2+ blocked 76% of 
the evoked ITail amplitude and reduced the Time-to-Baseline (not shown) by 85%. ITrsp was not 
significantly inhibited by Ba2+ (n=5). (B) Application of DHK inhibited up to 73% of ITrsp as did 
TBOA; however, to achieve this level of inhibition, DHK required twice as long incubation time 
(8.1±2.1 min, n=7). In the presence of DHK, ITail was strongly impaired compared to the control. 
Bar graph showing that DHK reduced ITail amplitude by up to 62% and the time-to-baseline by 
48%. Data are shown for a DHK incubation time of 4 min (white bars) and for a time 
corresponding to the maximal ITrsp inhibition (black bars). (C) I-V-curve before (open circles) and 
during (black diamonds) DHK superfusion (n=4) showing a decreased slope (increased input 
resistance) and change of equilibrium potential towards more positive values. 
Figure 1
Figure 2
Figure 3
